|1.||Dalmau, Josep: 64 articles (09/2015 - 01/2007)|
|2.||Hashimoto, Kenji: 34 articles (03/2015 - 02/2002)|
|3.||Vincent, Angela: 32 articles (11/2015 - 12/2008)|
|4.||Javitt, Daniel C: 29 articles (05/2015 - 07/2002)|
|5.||Coyle, Joseph T: 28 articles (06/2015 - 01/2002)|
|6.||Zhang, Guang-Yi: 25 articles (06/2012 - 11/2002)|
|7.||Deutsch, Stephen I: 24 articles (08/2015 - 08/2002)|
|8.||Krystal, John H: 23 articles (03/2015 - 07/2002)|
|9.||Takahashi, Yukitoshi: 20 articles (08/2015 - 01/2005)|
|10.||Gardoni, Fabrizio: 20 articles (01/2015 - 01/2002)|
04/08/2002 - "NMDA antagonists derived from 5-phosphonomethyl-1,4-dihydroquinoxaline-2,3-dione (3a) are potent anticonvulsant agents, and display strong protective effects in the electroshock-induced convulsion assay in mice. "
11/16/1993 - "Prior administration of CPA resulted either in a delay of seizure onset and unchanged mortality (0.5 mg/kg CPA, 60 mg/kg NMDA) or in elimination of tonic episodes and a significant reduction in postictal mortality (1, 2 mg/kg CPA; 60, 125 mg/kg NMDA). "
03/25/2013 - "However, in field conditions, treatment may be delayed and with the exception of NMDA receptor antagonists, currently no drug provides protection (against lethality, seizures, SRBD and neurological consequences) when seizures are left unabated for one hour or more. "
08/01/2011 - "Stress-associated alterations in seizure susceptibility and diminished efficacy of antiseizure medications in humans have been reported [Joëls, 2009; Haut et al., 2007; Moshe et al., 2008]; thus, these experimental observations implicate altered endogenous tone of NMDA receptor-mediated neurotransmission in clinically adverse effects of stress on seizure proneness and treatment. "
04/01/1990 - "We report experiments performed to determine if NMDA receptor antagonists are effective in stopping seizures in the late stages of SE. "
|2.||Schizophrenia (Dementia Praecox)
04/01/2014 - "Are NMDA receptor antagonists beneficial in the treatment of schizophrenia?"
05/01/2009 - "In summary, these data demonstrate that PCP-induced deficits in NMDA receptor function, neurotoxicity and subsequent behavioral deficits may be prevented by D1R activation in the cortex and further, it is suggested that D1R activation may be beneficial in treating schizophrenia."
02/01/2004 - "Overall, the findings indicate that agents which potentiate NMDA transmission may be therapeutically beneficial in treatment of persistent symptoms of schizophrenia."
01/01/2009 - "Through the study of these models, our improved understanding of how the brain adapts to persistent NMDA receptor hypofunction may eventually suggest new therapeutic strategies for schizophrenia."
01/01/2013 - "Our work has implications for the preclinical use of NMDA receptor antagonists in the prediction of potential therapeutic efficacy in the search for novel treatments for schizophrenia. "
10/01/2003 - "Among NMDA receptor subtypes, the NR2B subunit-containing receptors appear particularly important for nociception, thus leading to the possibility that NR2B-selective antagonists may be useful in the treatment of chronic pain."
03/01/2006 - "We conclude that adjuvant chronic pain treatment with N-methyl-d-aspartate receptor antagonists might be beneficial for chronic pain if enhanced sensitization is involved and that the quantitative sensory test of temporal summation may be used to verify this."
01/01/2000 - "Thus, provided their therapeutic ratio is favorable, NMDA-receptor antagonists may be effective in the treatment of some types of chronic pain."
01/01/2002 - "Many of these compounds have demonstrated efficacy in animal models of chronic pain, and some of them appear to have a reduced side-effect liability compared to clinically tested NMDA antagonists. "
08/01/2004 - "These results confirm low efficacy of acute administration of NMDA receptor antagonists in the models of established pain states. "
08/01/1991 - "We conclude that systemically administered noncompetitive NMDA receptor antagonists do not provide a marked protection against neuronal damage after a transient period of severe forebrain ischemia."
12/01/1992 - "Recent therapeutic studies have demonstrated the efficacy of non-NMDA receptor antagonists in experimental studies of global ischemia."
12/01/1997 - "-(S)-Alpha-phenyl-2-pyridine-ethanamine Dihydrochloride-, a low affinity uncompetitive N-methyl-D-aspartic acid antagonist, is effective in rodent models of global and focal ischemia."
01/09/2009 - "In summary, our data demonstrate an in vivo rodent model of ischemic tolerance in which 30 min of neuronal preconditioning with 10 microM NMDA confers protection against a 4 h period of MCAO-induced ischemia. "
06/01/2008 - "NMDA receptor blocker ameliorates ischemia-reperfusion-induced renal dysfunction in rat kidneys."
|5.||Neuralgia (Stump Neuralgia)
08/01/2009 - "Although NMDA antagonists are highly effective in reducing neuropathic pain, these agents cause severe side effects at therapeutic doses, which limit their clinical uses. "
08/01/1995 - "We conclude that NMDA antagonists may have promise for the treatment of neuropathic pain, but strategies are needed to improve their therapeutic ratio, such as intrathecal administration or systemic treatment with more selective drugs."
01/01/2008 - "NMDA antagonists may be effective in many neuropathic pain states. "
04/20/1998 - "The present results suggest that a combination of NMDA-antagonist and opiates might be effective in treating neuropathic pain. "
04/02/1999 - "[NMDA receptor antagonists: a new treatment for neuropathic pain]."
|2.||Dizocilpine Maleate (Dizocilpine)
|5.||Glutamic Acid (Glutamate)
|6.||N-Methyl-D-Aspartate Receptors (NMDA Receptors)
|7.||Glycine (Aminoacetic Acid)
|8.||alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
|9.||Glutamate Receptors (Glutamate Receptor)
|10.||Kainic Acid (Kainate)
|3.||Drug Therapy (Chemotherapy)